Literature DB >> 12385777

The peak height ratio of S-sulfonated transthyretin and other oxidized isoforms as a marker for molybdenum cofactor deficiency, measured by electrospray ionization mass spectrometry.

Masahiko Kishikawa1, Jörn Oliver Sass, Nobuo Sakura, Toyofumi Nakanishi, Akira Shimizu, Masanori Yoshioka.   

Abstract

Molybdenum cofactor deficiency is a fatal neurological disorder, which follows an autosomal-recessive trait and is characterized by combined deficiency of the enzyme, sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase. Early detection of molybdenum cofactor-deficient patients is essential for their proper care and genetic counseling of families at risk. We demonstrate the use of S-sulfonated transthyretin (TTR) as a marker for molybdenum cofactor deficiency. Plasma or sera obtained from 4 patients with molybdenum cofactor deficiency and 57 controls were studied by electrospray ionization mass spectrometry (ESIMS) following selective enrichment of TTR by immunoprecipitation using protein G/A agarose. The data obtained from molybdenum cofactor deficiency samples indicated a strong increase in the peak height of S-sulfonated TTR. A more significant difference was revealed if the peak height ratio of S-sulfonated TTR and the sum of the other oxidized TTR were determined. By accurate determination of the ratio, the samples of molybdenum cofactor deficiency patients could clearly be distinguished from controls without molybdenum cofactor deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385777     DOI: 10.1016/s0925-4439(02)00156-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Hypohomocysteinaemia and highly increased proportion of S-sulfonated plasma transthyretin in molybdenum cofactor deficiency.

Authors:  J O Sass; M Kishikawa; R Puttinger; J Reiss; W Erwa; A Shimizu; W Sperl
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

2.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Authors:  Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

3.  Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.

Authors:  Olgica Trenchevska; Elena Kamcheva; Dobrin Nedelkov
Journal:  Proteomics       Date:  2011-08-09       Impact factor: 3.984

4.  Alteration of transthyretin microheterogeneity in serum of multiple trauma patients.

Authors:  Beate Gericke; Jens Raila; Maria Deja; Sascha Rohn; Bernd Donaubauer; Britta Nagl; Sophie Haebel; Florian J Schweigert; Udo Kaisers
Journal:  Biomark Insights       Date:  2007-08-08

Review 5.  Homeostatic impact of sulfite and hydrogen sulfide on cysteine catabolism.

Authors:  Joshua B Kohl; Anna-Theresa Mellis; Guenter Schwarz
Journal:  Br J Pharmacol       Date:  2018-09-27       Impact factor: 8.739

6.  Post-translational modifications of transthyretin affect the triiodonine-binding potential.

Authors:  Andrea Henze; Thomas Homann; Mustafa Serteser; Ozge Can; Ozlem Sezgin; Abdurrahman Coskun; Ibrahim Unsal; Florian J Schweigert; Aysel Ozpinar
Journal:  J Cell Mol Med       Date:  2014-10-14       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.